OCS OCULIS HOLDING AG

Oculis to Present at Upcoming May Investor Conferences

Oculis to Present at Upcoming May Investor Conferences

ZUG, Switzerland, May 07, 2025 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS / ICX: OCS.IC) (“Oculis”), a global biopharmaceutical company focused on innovations addressing ophthalmic and neuro-ophthalmic diseases with significant unmet medical needs, today announced that Oculis will be attending and presenting at the following upcoming investor conferences:

Bio€quity Europe

May 12-14, 2025; Bruges, Belgium

Company update by Riad Sherif, MD, Chief Executive Officer, on May 14 at 11am CET

Bank of America Healthcare Conference

May 13-15, 2025; Las Vegas, USA

Fireside chat with Sylvia Cheung, Chief Financial Officer, on May 14 at 3pm PT

H.C. Wainwright Annual BioConnect at Nasdaq

May 20, 2025; New York, USA

Company update by Sylvia Cheung, Chief Financial Officer, on May 20 at 9:30am ET

Stifel Virtual Ophthalmology Forum

May 27, 2025; Virtual

Fireside chat with Sylvia Cheung, Chief Financial Officer, on May 27 at 1pm ET

The Company will be available for one-on-one meetings during the conferences. Interested investors should contact their respective representative at the sponsoring institutions to request meetings.

Webcast links, when available, will be posted to the Oculis website on the  page under the Investors & Media section.

-ENDS-

About Oculis

Oculis is a global biopharmaceutical company (Nasdaq: OCS; XICE: OCS) focused on innovations addressing ophthalmic and neuro-ophthalmic diseases with significant unmet medical needs. Oculis’ highly differentiated pipeline of multiple innovative product candidates in development includes: OCS-01, a topical eye drop candidate for diabetic macular edema (DME); Privosegtor (OCS-05), a neuroprotective candidate for acute optic neuritis with potentially broad clinical applications in other neuro-ophthalmic diseases and Licaminlimab (OCS-02), a topical biologic anti-TNFα eye drop candidate for dry eye disease (DED). Headquartered in Switzerland with operations in the U.S. and Iceland, Oculis is led by an experienced management team with a successful track record and supported by leading international healthcare investors.

For more information, please visit:

Oculis Contacts

Ms. Sylvia Cheung, CFO

Investor Relations

LifeSci Advisors

Corey Davis, Ph.D.

Media Relations

ICR Healthcare

Amber Fennell / David Daley / Sean Leous



EN
07/05/2025

Underlying

OCSOCULIS HOLDING AG

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on OCULIS HOLDING AG

 PRESS RELEASE
Free
OCS OCULIS HOLDING ...

Oculis Publishes Invitation to the Annual General Meeting

Oculis Publishes Invitation to the Annual General Meeting ZUG, Switzerland, May 09, 2025 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS / ICX: OCS.IC) (“Oculis”), today published the invitation to the 2025 Annual General Meeting, which will be held on June 4, 2025 at Ochsen-Zug, Kolinplatz 11, CH-6300 Zug, Switzerland, at 3:00 p.m. CEST / 9:00 a.m. EDT. The 2025 Annual General Meeting will be held in-person and broadcast. To join the broadcast, please use the following . Information pertaining to the 2025 Annual General Meeting, including meeting materials, can be accessed on the Ocu...

May 9, 2025 1 EN
 PRESS RELEASE
Free
OCS OCULIS HOLDING ...

Oculis Publishes Invitation to the Annual General Meeting

Oculis Publishes Invitation to the Annual General Meeting ZUG, Switzerland, May 09, 2025 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS / ICX: OCS.IC) (“Oculis”), today published the invitation to the 2025 Annual General Meeting, which will be held on June 4, 2025 at Ochsen-Zug, Kolinplatz 11, CH-6300 Zug, Switzerland, at 3:00 p.m. CEST / 9:00 a.m. EDT. The 2025 Annual General Meeting will be held in-person and broadcast. To join the broadcast, please use the following . Information pertaining to the 2025 Annual General Meeting, including meeting materials, can be accessed on the...

May 9, 2025 1 EN
 PRESS RELEASE
Free
OCS OCULIS HOLDING ...

Oculis birtir boð á aðalfund

Oculis birtir boð á aðalfund ZUG, Sviss, May 09, 2025 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS / ICX: OCS.IC) („Oculis“), birti í dag boð á aðalfundinn 2025 sem haldinn verður 4. júní 2025 í Ochsen-Zug, Kolinplatz 11, CH-6300 Zug, Sviss, klukkan 13:00 að íslenskum tíma / 15:00 CEST / 09:00 EDT. Aðalfundurinn 2025 verður staðfundur og ekki er boðið upp á rafræna þátttöku. Hægt verður að fylgjast með fundinum í gegnum vefstreymi með því að nota eftirfarandi . Allar upplýsingar varðandi aðalfundinn 2025, þ.m.t. fundarefni, er hægt að nálgast á vefsvæði Oculis . Í aðdraganda aðalf...

May 9, 2025 1 EN
 PRESS RELEASE
Free
OCS OCULIS HOLDING ...

Oculis Reports Q1 Financial Results and Provides Company Update

Oculis Reports Q1 Financial Results and Provides Company Update ZUG, Switzerland, May 08, 2025 (GLOBE NEWSWIRE) -- The recent R&D Day () showcased material progress across all three core assets and highlighted potential first-in-class neuroprotection treatment in neuro-ophthalmology, an area of high unmet medical need, thanks to Privosegtor’s (OCS-05) positive results from the ACUITY trial in Acute Optic NeuritisOCS-01: DIAMOND Ph3 trials enrollment completed with over 800 patients randomized; topline results expected Q2 2026 for the first potential eye drop treatment for diabetic macular...

May 8, 2025 1 EN
 PRESS RELEASE
Free
OCS OCULIS HOLDING ...

Oculis birtir uppgjör fyrir fyrsta ársfjórðung 2025 og kynnir áfanga í...

Oculis birtir uppgjör fyrir fyrsta ársfjórðung 2025 og kynnir áfanga í rekstri félagsins ZUG, Sviss, May 08, 2025 (GLOBE NEWSWIRE) -- Á kynningardegi um rannsókna- og þróunarstarf félagsins, sem haldinn var fyrir skömmu (), var umtalsverð framvinda fyrir öll þrjú kjarna þróunarlyf félagsins kynnt og áhersla lögð á hugsanlega taugaverndandi meðferð við augntaugasjúkdómum, sem væri fyrst sinnar tegundar og myndi uppfylla verulegar óuppfylltar læknisfræðilegar þarfir, þökk sé jákvæðum niðurstöðum Privosegtor (OCS-05) úr ACUITY-rannsókninni fyrir bráða sjóntaugabólgu OCS-01: Innritun í DIAMON...

May 8, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch